Per-protocol survival improved versus earlier cutoffs, with 35% alive beyond 30 months and 13% beyond 50 months after two ...

Amini: I believe this is critical for all stages of NSCLC. Whether you are in a small rural practice, large community or academic setting, having a team that you can communicate with is critical.

TACTI-004 planned ~756 patients across >150 sites and enrolled 378 by February 2026, including squamous and nonsquamous NSCLC irrespective of PD-L1 status. Randomization compared eftilagimod alfa plus ...

Amini: This varies quite a bit by stage — operable vs. nonoperable — and patients’ performance status and preference. Additionally, more relevant to medical oncology but equally, if not more, ...

In Personalized Selection of Immunotherapy Strategies in Metastatic NSCLC and Future Evidence Gaps, our experts delve into the following critical questions: We have now covered se ...

UPPSALA, SE / ACCESS Newswire / March 18, 2026 / Biovica International (STO:BIOVIC-B)(STO:BIOVIC.B)(FRA:9II) - Biovica, a leader in blood-based biomarkers for cancer treatment monitoring, today ...

Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced ...

Illumina and Labcorp expand collaboration to advance precision oncology through innovative applications of NGS solutions: San Diego Friday, March 20, 2026, 15:00 Hrs [IST] Illumin ...

Andreas Lundqvist's group will use Pixelgen's Proximity Network Assay to explore spatial distribution and abundance of single cell surface proteins in non-small cell lung cancer STOCKHOLM, March 17, ...

In the U.S., FDA approval establishes Opdivo in combination with doxorubicin, vinblastine and dacarbazine (AVD) as the first immunotherapy combination approved for adult and pediatric patients 12 ...

Experts explain stage IV lung cancer goals, PD‑L1-driven therapy choices, and when to intensify with chemo plus dual immunotherapy. Led by Dr. Dietrich, Drs. Niu, Nadler, and Dowlati discussed the ...